Home- Conferences
- Program
- Discovery & Development Forum
- Translational Bioinformatics
- Systems Biology
- Blood Brain Barrier
- Predictive Toxicology
- Berg, E
- Bhal, S
- Bryant, S
- Elkin, P
- Floudas, C
- Fraczkiewicz, R
- Hardy, B
- Judson, R
- Mu, F
- No, K
- Patlewicz, G
- Pelekis, M
- Poroikov, V
- Tsaioun, K
- Location
- Sponsors & Exhibitors
- Call for Contributions
- Bursary Awards
- Poster Session
- Photo Gallery
- Workshops & Training
- Program
- Registration
- About
- Overview
- Contact
- Support
- Schedule
|
|
|
|
|
|
|
|
|
| About Ellen Berg (BioSeek, Inc.) |
|
Ellen L. Berg is Chief Scientific Officer at BioSeek, Inc. in Burlingame, California, where she leads the development of the company’s BioMAP platform of primary human cell-based disease models and research in predictive drug safety and efficacy. Dr. Berg received her Ph.D. from the Department of Biochemistry, Cell Biology and Molecular Biology at Northwestern University and was a postdoctoral fellow at Stanford University. Prior to founding BioSeek in 2000, Dr. Berg led a research group at Protein Design Labs, Inc. developing novel therapeutic antibodies for inflammatory diseases. Her research interests include mechanisms of inflammatory disease and vascular biology, the regulation of cell signaling networks, and new approaches for the discovery of novel therapeutics. Dr. Berg is co-inventor of a number of patents in the field of inflammation biology and has authored over 60 publications in peer-reviewed journals.
|
|
Defining Chemical Target and Pathway Toxicity Mechanisms with Primary Human Cell Systems
Ellen L. Berg (BioSeek, Inc., Burlingame, California)
Predicting the health effects resulting from drug or chemical exposure from in vitro assays is important for drug discovery as well as for prioritizing chemicals for in vivo toxicology studies. While primary human cell-based assays offer the opportunity to assess chemical effects in settings that are more relevant to human exposure, there are significant challenges. The BioMAP Systems platform involves the statistical analysis of disease biomarker endpoints generated from primary human cell-based disease models for drug selection and characterization. BioMAP systems have been developed for a broad range of cell types and tissue settings relevant to inflammatory, autoimmune, cardiovascular, respiratory and cancer biology. The design and performance of BioMAP systems as a platform for predictive toxicity will be presented including examples of both on-target (kinase) and off-target (nuclear hormone receptor) effects. Results from BioMAP profiling for the EPA’s ToxCast program will also be discussed.
|
|
|
|
|
|
|
|
|
|
|
